The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.
 
Daniel J Khalaf
Consulting or Advisory Role - Bayer
 
Katherine Sunderland
No Relationships to Disclose
 
Bernhard J. Eigl
Honoraria - AstraZeneca; Janssen; Merck; Pfizer; Roche Canada
Consulting or Advisory Role - AstraZeneca; Janssen; Merck; Roche Canada
Travel, Accommodations, Expenses - Janssen
 
Daygen L. Finch
Honoraria - Astellas Oncology; Bayer; Janssen
 
Conrad D. Oja
No Relationships to Disclose
 
Joanna Vergidis
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Merck; Pfizer
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Merck
 
Muhammad Zulfiqar
No Relationships to Disclose
 
Christian K. Kollmannsberger
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Novartis; Pfizer
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer
 
Martin Gleave
Stock and Other Ownership Interests - OncoGenex
Honoraria - Astellas Pharma; Bayer; Genova Diagnostics; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genova Diagnostics; Janssen; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bayer; Janssen
Patents, Royalties, Other Intellectual Property - OncoGenex - OGX-011, OGX-427; ST-CP; ST-POP
 
Kim N. Chi
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; ESSA; Janssen; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly/ImClone (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)